Avadel Pharmaceuticals plc (AVDL) Financials
Stock symbol AVDL is outdated, potentially delisted? Maybe it is available on other exchange?
AVDL Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| Sept. 30, 2025 | 199.4 million | 101.2 million |
| June 30, 2025 | 187.2 million | 96.4 million |
| March 31, 2025 | 167.9 million | 93.9 million |
| Dec. 31, 2024 | 164.2 million | 90.4 million |
AVDL Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| Sept. 30, 2025 | 23.2 million | 4.9 million |
| June 30, 2025 | 12.5 million | 5.3 million |
| March 31, 2025 | -8.2 million | 4.2 million |
| Dec. 31, 2024 | 7.9 million | 4.1 million |
AVDL Net Income
No data available :(
AVDL Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| Sept. 30, 2025 | 91.6 million | 36.6 million | 1.8 million |
| June 30, 2025 | 81.5 million | 2.0 million | 2.7 million |
| March 31, 2025 | 66.5 million | 2.2 million | 2.9 million |
| Dec. 31, 2024 | 73.8 million | 1.1 million | 1.7 million |
AVDL Shares Outstanding
AVDL Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| Sept. 30, 2025 | 10760 | 27.0 million | 51.5 million | - |
| June 30, 2025 | 181000 | 4.3 million | 48.6 million | - |
| March 31, 2025 | - | 4.4 million | 45.6 million | - |
| Dec. 31, 2024 | - | 4.3 million | 44.6 million | - |
AVDL Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| Sept. 30, 2025 | 77.5 million | -3.0 million |
| June 30, 2025 | 68.1 million | 6.4 million |
| March 31, 2025 | 52.5 million | 5.6 million |
| Dec. 31, 2024 | 50.4 million | 4.8 million |
AVDL Revenue by Segment
Graph available only for paid members. Upgrade to see it.
AVDL
Price: $21.64
52 week price:
Earnings Per Share: -0.02 USD
P/E Ratio: -1084.50
Exchange: NGM
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Country: Ireland
Volume: 237800
Ebitda: 27.2 millionMarket Capitalization: 2.1 billion